Replimune Group (NASDAQ:REPL) CFO Sells $148,480.56 in Stock

Replimune Group, Inc. (NASDAQ:REPL) CFO Emily Luisa Hill sold 11,448 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $148,480.56. Following the transaction, the chief financial officer owned 225,108 shares in the company, valued at $2,919,650.76. This trade represents a 4.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Replimune Group Stock Down 1.4%

Shares of NASDAQ:REPL opened at $14.97 on Friday. The firm has a market capitalization of $1.26 billion, a P/E ratio of -4.43 and a beta of 0.88. The company has a debt-to-equity ratio of 0.63, a quick ratio of 4.79 and a current ratio of 4.79. The stock has a 50 day moving average price of $10.66 and a 200-day moving average price of $7.79. Replimune Group, Inc. has a 52-week low of $1.50 and a 52-week high of $15.70.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.03). As a group, equities research analysts anticipate that Replimune Group, Inc. will post -2.7 EPS for the current fiscal year.

Replimune Group News Roundup

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: FDA approval creates a commercial opportunity: Replimune announced that TUDRIQEV™ (RP1) in combination with nivolumab received FDA accelerated approval for advanced melanoma. The company expects to launch the treatment within 60 days, potentially allowing it to begin generating commercial revenue and validating its oncolytic-immunotherapy platform. Replimune fiscal first-quarter 2027 results and corporate update
• Positive Sentiment: Financing supports the launch: A recently completed $150 million financing extends Replimune’s cash runway and is intended to fund the commercial rollout and confirmatory trial required under the accelerated-approval pathway. The added liquidity reduces near-term funding concerns, though the offering may dilute existing shareholders. Replimune corporate update
• Positive Sentiment: Commercial leadership added: Michelle DiNapoli was appointed chief commercial officer, strengthening the company’s preparations for its first product launch.
• Neutral Sentiment: Insider sales were attributed to taxes: The CEO, CFO, CAO and another insider sold shares totaling approximately $906,000. SEC filings indicate the transactions covered tax withholding tied to vested equity awards, and the executives retained significant holdings, limiting the negative signal.
• Negative Sentiment: Quarterly loss slightly exceeded expectations: Replimune reported a fiscal first-quarter loss of $0.72 per share versus the consensus estimate of a $0.69 loss. As a commercial-stage biotechnology company, it remains unprofitable and is expected to post a substantial full-year loss.
• Negative Sentiment: Securities litigation remains an overhang: Multiple law firms are promoting a class action covering investors who bought REPL shares from October 20, 2025, through April 10, 2026. The lawsuit alleges misleading statements about RP1 and FDA study-design issues; the allegations have not been proven. The lead-plaintiff deadline is October 5, 2026. Replimune securities lawsuit deadline alert

Analyst Ratings Changes

A number of analysts have recently commented on REPL shares. Weiss Ratings cut shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Wall Street Zen upgraded shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd. Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. Cantor Fitzgerald reissued an “overweight” rating on shares of Replimune Group in a research report on Wednesday. Finally, BMO Capital Markets raised shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective on the stock in a research note on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $11.86.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Replimune Group by 17.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock worth $435,000 after acquiring an additional 6,653 shares in the last quarter. Millennium Management LLC grew its stake in shares of Replimune Group by 2.8% in the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock worth $11,927,000 after acquiring an additional 33,574 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Replimune Group by 20.9% during the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock valued at $6,729,000 after acquiring an additional 119,145 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Replimune Group by 6.9% during the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock valued at $948,000 after acquiring an additional 6,616 shares in the last quarter. Finally, Sei Investments Co. raised its position in shares of Replimune Group by 149.5% in the 2nd quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock worth $283,000 after purchasing an additional 18,263 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.